New pill aims to slow lung scarring in IPF patients
Disease control
Recruiting now
This phase 2 trial tests an oral drug called PIPE-791 in 324 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either a low or high dose of PIPE-791 or a placebo daily for several months. The main goal is t…
Phase: PHASE2 • Sponsor: Contineum Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC